<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Biocon Limited — News on 6ix</title>
<link>https://6ix.com/company/biocon-limited</link>
<description>Latest news and press releases for Biocon Limited on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 21 Apr 2026 12:49:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/biocon-limited" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683649ed78dffbe2df152b5d.webp</url>
<title>Biocon Limited</title>
<link>https://6ix.com/company/biocon-limited</link>
</image>
<item>
<title>Press Release Apr 21 2026</title>
<link>https://6ix.com/company/biocon-limited/news/press-release-apr-21-2026-5</link>
<guid isPermaLink="true">https://6ix.com/company/biocon-limited/news/press-release-apr-21-2026-5</guid>
<pubDate>Tue, 21 Apr 2026 12:49:00 GMT</pubDate>
<description>Biocon Limited has informed the Exchange regarding a press release dated April 21, 2026, titled "Biocon Receives Health Canada Approval of Bosaya (Denosumab) and Vevzuo (Denosumab), Biosimilars to Prolia® and Xgeva®".</description>
</item>
<item>
<title>Biocon Receives Health Canada Approval of Bosaya™ (Denosumab) and Vevzuo™ (Denosumab), Biosimilars to Prolia® and Xgeva®</title>
<link>https://6ix.com/company/biocon-limited/news/biocon-receives-health-canada-approval-of-bosayatm-denosumab-and-vevzuotm-denosumab-biosimilars-to-proliar-and-xgevar</link>
<guid isPermaLink="true">https://6ix.com/company/biocon-limited/news/biocon-receives-health-canada-approval-of-bosayatm-denosumab-and-vevzuotm-denosumab-biosimilars-to-proliar-and-xgevar</guid>
<pubDate>Tue, 21 Apr 2026 11:05:00 GMT</pubDate>
<description>TORONTO & BENGALURU, India, April 21, 2026--Biocon Receives Health Canada Approval of Bosaya™ and Vevzuo™ (Denosumab biosimilars to Prolia® and Xgeva®) for bone health.</description>
</item>
<item>
<title>Press Release Apr 07 2026</title>
<link>https://6ix.com/company/biocon-limited/news/press-release-apr-07-2026-22</link>
<guid isPermaLink="true">https://6ix.com/company/biocon-limited/news/press-release-apr-07-2026-22</guid>
<pubDate>Tue, 07 Apr 2026 20:07:06 GMT</pubDate>
<description>Biocon Limited has informed the Exchange regarding a press release dated April 07, 2026, titled "Biocon Announces U.S. Commercial Launch of Bosaya and Aukelso , Denosumab Biosimilars".</description>
</item>
<item>
<title>Press Release Mar 27 2026</title>
<link>https://6ix.com/company/biocon-limited/news/press-release-mar-27-2026-5</link>
<guid isPermaLink="true">https://6ix.com/company/biocon-limited/news/press-release-mar-27-2026-5</guid>
<pubDate>Fri, 27 Mar 2026 16:07:31 GMT</pubDate>
<description>Biocon Limited has informed the Exchange regarding a press release dated March 27, 2026, titled "Shreehas Tambe Appointed CEO & Managing Director of Biocon Limited, Effective April 1, 2026".</description>
</item>
<item>
<title>Press Release Feb 24 2026</title>
<link>https://6ix.com/company/biocon-limited/news/press-release-feb-24-2026-2</link>
<guid isPermaLink="true">https://6ix.com/company/biocon-limited/news/press-release-feb-24-2026-2</guid>
<pubDate>Wed, 25 Feb 2026 02:04:05 GMT</pubDate>
<description>Biocon Limited has informed the Exchange regarding a press release dated February 24, 2026, titled "Biocon obtains approval for weight management drug,Liraglutide, in the United States".</description>
</item>
<item>
<title>Press Release Feb 12 2026</title>
<link>https://6ix.com/company/biocon-limited/news/press-release-feb-12-2026-6</link>
<guid isPermaLink="true">https://6ix.com/company/biocon-limited/news/press-release-feb-12-2026-6</guid>
<pubDate>Fri, 13 Feb 2026 00:42:24 GMT</pubDate>
<description>Biocon Limited has informed the Exchange regarding a press release dated February 12, 2026, titled "Biocon Q3FY26 Operating Revenue at Rs 4,173 Cr Q3FY26 EBITDA at Rs 951 Cr Q3FY26 Net Profit at Rs 144 Cr ".</description>
</item>
<item>
<title>Press Release Feb 07 2026</title>
<link>https://6ix.com/company/biocon-limited/news/press-release-feb-07-2026-3</link>
<guid isPermaLink="true">https://6ix.com/company/biocon-limited/news/press-release-feb-07-2026-3</guid>
<pubDate>Sat, 07 Feb 2026 18:03:05 GMT</pubDate>
<description>Biocon Limited has informed the Exchange regarding a press release dated February 07, 2026, titled "Fitch Ratings Upgrades Biocon Biologics Outlook from Stable to Positive ".</description>
</item>
<item>
<title>Press Release Jan 28 2026</title>
<link>https://6ix.com/company/biocon-limited/news/press-release-jan-28-2026-18</link>
<guid isPermaLink="true">https://6ix.com/company/biocon-limited/news/press-release-jan-28-2026-18</guid>
<pubDate>Wed, 28 Jan 2026 13:46:02 GMT</pubDate>
<description>Biocon Limited has informed the Exchange regarding a press release dated January 28, 2026, titled "S&P Global Upgrades Biocon Biologics Credit Rating To BB+ Revises Outlook to Stable ".</description>
</item>
<item>
<title>Press Release Jan 15 2026</title>
<link>https://6ix.com/company/biocon-limited/news/press-release-jan-15-2026-8</link>
<guid isPermaLink="true">https://6ix.com/company/biocon-limited/news/press-release-jan-15-2026-8</guid>
<pubDate>Thu, 15 Jan 2026 14:16:55 GMT</pubDate>
<description>Biocon Limited has informed the Exchange regarding a press release dated January 14, 2026, titled "Biocon Limited Concludes Rs 4,150 Crore (app USD 460 million) Equity Fundraise through a Qualified Institutions Placement (QIP)".</description>
</item>
<item>
<title>Press Release Jan 06 2026</title>
<link>https://6ix.com/company/biocon-limited/news/press-release-jan-06-2026-5</link>
<guid isPermaLink="true">https://6ix.com/company/biocon-limited/news/press-release-jan-06-2026-5</guid>
<pubDate>Tue, 06 Jan 2026 22:34:33 GMT</pubDate>
<description>Biocon Limited has informed the Exchange regarding a press release dated January 06, 2026, titled "Biocon Biologics to Expand Biosimilar Oncology Portfolio, Outline Strategic Vision at the 2026 J.P. Morgan Healthcare Conference.".</description>
</item>
<item>
<title>Biocon Biologics to Expand Biosimilar Oncology Portfolio, Outline Strategic Vision at the 2026 J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/biocon-limited/news/biocon-biologics-to-expand-biosimilar-oncology-portfolio-outline-strategic-vision-at-the-2026-jp-morgan-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/biocon-limited/news/biocon-biologics-to-expand-biosimilar-oncology-portfolio-outline-strategic-vision-at-the-2026-jp-morgan-healthcare-conference</guid>
<pubDate>Tue, 06 Jan 2026 12:26:00 GMT</pubDate>
<description>•New oncology assets to include proposed biosimilars for Trastuzumab/Hyaluronidase combination (Herceptin® SC/Herceptin HYLECTA™), Nivolumab (Opdivo®) and Pembrolizumab (Keytruda®) •Company to outline integration as a wholly owned subsidiary into Biocon Ltd., strengthening its global leadership in biosimilar insulins and GLP 1 peptide generics to cover the full spectrum of diabetes careBRIDGEWATER, N.J., United States and BENGALURU, Karnataka, India, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Biocon Biol</description>
</item>
<item>
<title>Press Release Dec 23 2025</title>
<link>https://6ix.com/company/biocon-limited/news/press-release-dec-23-2025-7</link>
<guid isPermaLink="true">https://6ix.com/company/biocon-limited/news/press-release-dec-23-2025-7</guid>
<pubDate>Tue, 23 Dec 2025 22:34:32 GMT</pubDate>
<description>Biocon Limited has informed the Exchange regarding a press release dated December 23, 2025, titled "Biocon Limited signs out-licensing agreement with Ajanta to market Semaglutide in 26 countries".</description>
</item>
<item>
<title>Press Release Dec 17 2025</title>
<link>https://6ix.com/company/biocon-limited/news/press-release-dec-17-2025-6</link>
<guid isPermaLink="true">https://6ix.com/company/biocon-limited/news/press-release-dec-17-2025-6</guid>
<pubDate>Wed, 17 Dec 2025 13:14:28 GMT</pubDate>
<description>Biocon Limited has informed the Exchange regarding a press release dated December 17, 2025, titled "Biocon Biologics Recognized as Asia IP Elite for 2025 by IAM.".</description>
</item>
<item>
<title>Press Release Dec 15 2025</title>
<link>https://6ix.com/company/biocon-limited/news/press-release-dec-15-2025-5</link>
<guid isPermaLink="true">https://6ix.com/company/biocon-limited/news/press-release-dec-15-2025-5</guid>
<pubDate>Mon, 15 Dec 2025 13:29:25 GMT</pubDate>
<description>Biocon Limited has informed the Exchange regarding a press release dated December 15, 2025, titled "Biocon Limited launches its Glucagon-like Peptide-1 (GLP -1), Liraglutide, in the Netherlands".</description>
</item>
<item>
<title>Press Release Dec 13 2025</title>
<link>https://6ix.com/company/biocon-limited/news/press-release-dec-13-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/biocon-limited/news/press-release-dec-13-2025-1</guid>
<pubDate>Sat, 13 Dec 2025 18:40:57 GMT</pubDate>
<description>Biocon Limited has informed the Exchange regarding a press release dated December 13, 2025, titled "Biocon Biologics Signs Settlement and License Agreement to Commercialize Biosimilar Aflibercept Worldwide".</description>
</item>
<item>
<title>Press Release Dec 11 2025</title>
<link>https://6ix.com/company/biocon-limited/news/press-release-dec-11-2025-2</link>
<guid isPermaLink="true">https://6ix.com/company/biocon-limited/news/press-release-dec-11-2025-2</guid>
<pubDate>Thu, 11 Dec 2025 18:16:00 GMT</pubDate>
<description>Biocon Limited has informed the Exchange regarding a press release dated December 11, 2025, titled "S&P Global Places Biocon Biologics on Positive CreditWatchOn Account of Accelerated Debt Reduction".</description>
</item>
<item>
<title>Press Release Dec 06 2025</title>
<link>https://6ix.com/company/biocon-limited/news/press-release-dec-06-2025-1</link>
<guid isPermaLink="true">https://6ix.com/company/biocon-limited/news/press-release-dec-06-2025-1</guid>
<pubDate>Sat, 06 Dec 2025 15:17:56 GMT</pubDate>
<description>Biocon Limited has informed the Exchange regarding a press release dated December 06, 2025, titled "Biocon Limited to Integrate Biocon Biologics Limited to Create a Unified Global Biopharmaceutical Leader".</description>
</item>
<item>
<title>Press Release Dec 02 2025</title>
<link>https://6ix.com/company/biocon-limited/news/press-release-dec-02-2025-5</link>
<guid isPermaLink="true">https://6ix.com/company/biocon-limited/news/press-release-dec-02-2025-5</guid>
<pubDate>Tue, 02 Dec 2025 14:04:34 GMT</pubDate>
<description>Biocon Limited has informed the Exchange regarding a press release dated December 02, 2025, titled "Biocon Biologics Secures Market Entry Date for Denosumab Biosimilars in Europe and Rest of the World®".</description>
</item>
<item>
<title>Press Release Nov 11 2025</title>
<link>https://6ix.com/company/biocon-limited/news/press-release-nov-11-2025-10</link>
<guid isPermaLink="true">https://6ix.com/company/biocon-limited/news/press-release-nov-11-2025-10</guid>
<pubDate>Wed, 12 Nov 2025 01:47:33 GMT</pubDate>
<description>Biocon Limited has informed the Exchange regarding a press release dated November 11, 2025, titled "Biocon Q2FY26 Operating Revenue at Rs 4,296 Cr, Up 20% EBITDA at Rs 928 crore; Up 29%; PBT (before exceptional items) at Rs 183 Cr, Up 153%".</description>
</item>
<item>
<title>Press Release Oct 23 2025</title>
<link>https://6ix.com/company/biocon-limited/news/press-release-oct-23-2025-7</link>
<guid isPermaLink="true">https://6ix.com/company/biocon-limited/news/press-release-oct-23-2025-7</guid>
<pubDate>Thu, 23 Oct 2025 12:13:28 GMT</pubDate>
<description>Biocon Limited has informed the Exchange regarding a press release dated October 23, 2025, titled "Biocon Biologics Receives Health Canada Approval for Yesintek and Yesintek I.V. (ustekinumab), a Biosimilar to Stelara®".</description>
</item>
</channel>
</rss>